We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 29, 2021

Molecular Determinants of Outcomes With Pembrolizumab vs Paclitaxel in Patients With Gastroesophageal Adenocarcinoma

Annals of Oncology

 

Additional Info

Annals of Oncology
Molecular Determinants of Clinical Outcomes With Pembrolizumab Versus Paclitaxel in a Randomized, Open-Label, Phase III Trial in Patients With Gastroesophageal Adenocarcinoma
Ann. Oncol 2021 Sep 01;32(9)1127-1136, K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, C Caglevic, HC Chung, K Muro, E Van Cutsem, J Kobie, R Cristescu, D Aurora-Garg, J Lu, CS Shih, D Adelberg, ZA Cao, CS Fuchs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading